InspireMD Historical Income Statement

NSPR Stock

USD 3.00 0.02 0.67%

Historical analysis of InspireMD income statement accounts such as Total Operating Expenses of 14.4 M can show how well InspireMD performed in making a profits. Evaluating InspireMD income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of InspireMD's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining InspireMD latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InspireMD is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in InspireMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in InspireMD Stock, please use our How to Invest in InspireMD guide.

About InspireMD Income Statement Analysis

InspireMD Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to InspireMD shareholders. The income statement also shows InspireMD investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

InspireMD Income Statement Chart

At this time, InspireMD's Income Tax Expense is relatively stable compared to the past year. As of 12/23/2024, Total Other Income Expense Net is likely to grow to about 1.4 M, while Selling General Administrative is likely to drop slightly above 8 M.

Selling General Administrative Other Operating Expenses Total Operating Expenses Total Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of InspireMD. It is also known as InspireMD overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Total Revenue

Total revenue comprises all receipts InspireMD generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from InspireMD's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into InspireMD current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in InspireMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in InspireMD Stock, please use our How to Invest in InspireMD guide.At this time, InspireMD's Income Tax Expense is relatively stable compared to the past year. As of 12/23/2024, Total Other Income Expense Net is likely to grow to about 1.4 M, while Selling General Administrative is likely to drop slightly above 8 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	3.7M	4.1M	4.4M	3.1M
Research Development	5.2M	7.8M	8.0M	4.3M

Cost Of Revenue Research Development

InspireMD income statement Correlations

	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Total Other Income Expense Net	Depreciation And Amortization	Total Revenue	Gross Profit	Research Development	Cost Of Revenue	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Interest Expense		0.05	0.27	-0.22	-0.2	-0.2	0.32	-0.63	-0.63	0.08	-0.95	0.28	0.06	0.33	0.05	-0.39	0.27	-0.47	0.22	0.03	-0.39	0.43	-0.49	0.01
Selling General Administrative	0.05		-0.07	0.09	0.1	0.09	-0.03	0.09	0.09	0.25	0.01	-0.64	0.68	0.77	0.29	0.21	-0.02	-0.82	-0.02	0.44	-0.08	0.62	-0.21	0.34
Other Operating Expenses	0.27	-0.07		-0.93	-0.93	-0.93	0.99	-0.83	-0.83	0.26	-0.11	0.62	0.34	0.14	0.71	0.45	0.66	-0.32	-0.17	0.32	0.31	0.29	0.21	0.46
Operating Income	-0.22	0.09	-0.93		1.0	1.0	-0.95	0.88	0.88	-0.34	0.03	-0.67	-0.17	-0.02	-0.73	-0.39	-0.74	0.32	0.42	-0.28	-0.44	-0.32	-0.33	-0.49
Ebit	-0.2	0.1	-0.93	1.0		1.0	-0.95	0.88	0.88	-0.34	0.03	-0.67	-0.18	-0.03	-0.74	-0.4	-0.75	0.32	0.43	-0.31	-0.46	-0.3	-0.36	-0.5
Ebitda	-0.2	0.09	-0.93	1.0	1.0		-0.95	0.87	0.88	-0.34	0.03	-0.66	-0.19	-0.04	-0.74	-0.4	-0.75	0.32	0.43	-0.31	-0.46	-0.3	-0.36	-0.5
Total Operating Expenses	0.32	-0.03	0.99	-0.95	-0.95	-0.95		-0.87	-0.87	0.28	-0.14	0.61	0.32	0.17	0.72	0.39	0.7	-0.38	-0.19	0.33	0.29	0.35	0.18	0.46
Income Before Tax	-0.63	0.09	-0.83	0.88	0.88	0.87	-0.87		1.0	-0.31	0.5	-0.66	-0.17	-0.17	-0.6	-0.17	-0.71	0.45	0.29	-0.28	-0.25	-0.39	-0.12	-0.39
Net Income	-0.63	0.09	-0.83	0.88	0.88	0.88	-0.87	1.0		-0.31	0.5	-0.66	-0.17	-0.17	-0.6	-0.17	-0.71	0.45	0.3	-0.28	-0.25	-0.39	-0.12	-0.39
Income Tax Expense	0.08	0.25	0.26	-0.34	-0.34	-0.34	0.28	-0.31	-0.31		-0.03	0.1	0.14	0.06	0.37	0.23	0.19	-0.35	-0.26	-0.02	0.42	0.28	-0.03	0.46
Total Other Income Expense Net	-0.95	0.01	-0.11	0.03	0.03	0.03	-0.14	0.5	0.5	-0.03		-0.18	-0.06	-0.3	0.03	0.36	-0.18	0.35	-0.29	-0.06	0.37	-0.24	0.45	0.11
Depreciation And Amortization	0.28	-0.64	0.62	-0.67	-0.67	-0.66	0.61	-0.66	-0.66	0.1	-0.18		-0.41	-0.54	0.39	-0.01	0.64	0.28	-0.18	-0.3	0.24	0.04	0.23	0.28
Total Revenue	0.06	0.68	0.34	-0.17	-0.18	-0.19	0.32	-0.17	-0.17	0.14	-0.06	-0.41		0.86	0.39	0.68	-0.01	-0.65	-0.07	0.63	0.23	0.38	0.14	0.44
Gross Profit	0.33	0.77	0.14	-0.02	-0.03	-0.04	0.17	-0.17	-0.17	0.06	-0.3	-0.54	0.86		0.15	0.24	-0.07	-0.81	-0.03	0.58	-0.05	0.51	-0.12	0.29
Research Development	0.05	0.29	0.71	-0.73	-0.74	-0.74	0.72	-0.6	-0.6	0.37	0.03	0.39	0.39	0.15		0.55	0.82	-0.44	-0.23	0.44	0.39	0.36	0.26	0.57
Cost Of Revenue	-0.39	0.21	0.45	-0.39	-0.4	-0.4	0.39	-0.17	-0.17	0.23	0.36	-0.01	0.68	0.24	0.55		0.1	-0.14	-0.36	0.44	0.69	0.02	0.61	0.5
Selling And Marketing Expenses	0.27	-0.02	0.66	-0.74	-0.75	-0.75	0.7	-0.71	-0.71	0.19	-0.18	0.64	-0.01	-0.07	0.82	0.1		-0.3	-0.17	0.25	0.2	0.29	0.12	0.33
Net Income From Continuing Ops	-0.47	-0.82	-0.32	0.32	0.32	0.32	-0.38	0.45	0.45	-0.35	0.35	0.28	-0.65	-0.81	-0.44	-0.14	-0.3		0.1	-0.5	0.08	-0.75	0.27	-0.37
Non Recurring	0.22	-0.02	-0.17	0.42	0.43	0.43	-0.19	0.29	0.3	-0.26	-0.29	-0.18	-0.07	-0.03	-0.23	-0.36	-0.17	0.1		-0.16	-0.79	-0.22	-0.79	-0.55
Non Operating Income Net Other	0.03	0.44	0.32	-0.28	-0.31	-0.31	0.33	-0.28	-0.28	-0.02	-0.06	-0.3	0.63	0.58	0.44	0.44	0.25	-0.5	-0.16		0.16	0.11	0.22	-0.02
Tax Provision	-0.39	-0.08	0.31	-0.44	-0.46	-0.46	0.29	-0.25	-0.25	0.42	0.37	0.24	0.23	-0.05	0.39	0.69	0.2	0.08	-0.79	0.16		-0.06	0.84	0.57
Interest Income	0.43	0.62	0.29	-0.32	-0.3	-0.3	0.35	-0.39	-0.39	0.28	-0.24	0.04	0.38	0.51	0.36	0.02	0.29	-0.75	-0.22	0.11	-0.06		-0.18	0.61
Net Interest Income	-0.49	-0.21	0.21	-0.33	-0.36	-0.36	0.18	-0.12	-0.12	-0.03	0.45	0.23	0.14	-0.12	0.26	0.61	0.12	0.27	-0.79	0.22	0.84	-0.18		0.44
Reconciled Depreciation	0.01	0.34	0.46	-0.49	-0.5	-0.5	0.46	-0.39	-0.39	0.46	0.11	0.28	0.44	0.29	0.57	0.5	0.33	-0.37	-0.55	-0.02	0.57	0.61	0.44

Click cells to compare fundamentals

InspireMD Account Relationship Matchups

InspireMD income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	42K	160K	157K	28K	25.2K	23.9K
Selling General Administrative	5.2M	6.1M	7.4M	8.4M	11.1M	8.0M
Other Operating Expenses	13.5M	12.9M	19.2M	23.9M	27.3M	16.1M
Operating Income	(9.8M)	(10.4M)	(14.7M)	(18.7M)	(21.1M)	(20.1M)
Ebit	(9.8M)	(10.4M)	(14.7M)	(18.7M)	(21.1M)	(20.1M)
Ebitda	(9.7M)	(10.2M)	(14.6M)	(18.5M)	(20.9M)	(19.9M)
Total Operating Expenses	10.6M	10.5M	15.5M	19.8M	23.0M	14.4M
Income Before Tax	(10.0M)	(10.5M)	(14.9M)	(18.5M)	(19.9M)	(20.8M)
Net Income	(10.0M)	(10.5M)	(14.9M)	(18.5M)	(19.9M)	(20.9M)
Total Other Income Expense Net	(200K)	(160K)	(157K)	250K	1.3M	1.4M
Depreciation And Amortization	158K	151K	161K	188K	232K	182.6K
Total Revenue	3.7M	2.5M	4.5M	5.2M	6.2M	3.3M
Gross Profit	756K	83K	754K	1.1M	1.8M	1.0M
Research Development	3.0M	2.2M	5.2M	7.8M	8.0M	4.3M
Cost Of Revenue	3.0M	2.4M	3.7M	4.1M	4.4M	3.1M
Selling And Marketing Expenses	2.4M	2.1M	2.9M	3.7M	3.9M	3.3M
Net Income From Continuing Ops	(10.0M)	(10.5M)	(14.9M)	(18.5M)	(19.9M)	(20.9M)
Net Income Applicable To Common Shares	(10.0M)	(10.5M)	(14.9M)	(18.5M)	(21.3M)	(22.3M)
Net Interest Income	(200K)	(160K)	(157K)	250K	1.3M	1.4M
Reconciled Depreciation	158K	151K	161K	188K	232K	191.7K

Pair Trading with InspireMD

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InspireMD position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InspireMD will appreciate offsetting losses from the drop in the long position's value.

Moving together with InspireMD Stock

0.64	EW	Edwards Lifesciences Corp	Pair Corr
0.69	GH	Guardant Health	Pair Corr

Moving against InspireMD Stock

0.63	ENSG	Ensign Group	Pair Corr
0.62	DRIO	DarioHealth Corp	Pair Corr
0.6	EDAP	EDAP TMS SA	Pair Corr
0.49	VTAK	Catheter Precision	Pair Corr
0.49	EKSO	Ekso Bionics Holdings	Pair Corr

The ability to find closely correlated positions to InspireMD could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InspireMD when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InspireMD - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InspireMD to buy it.

The correlation of InspireMD is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InspireMD moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InspireMD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for InspireMD can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for InspireMD Stock Analysis

When running InspireMD's price analysis, check to measure InspireMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InspireMD is operating at the current time. Most of InspireMD's value examination focuses on studying past and present price action to predict the probability of InspireMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InspireMD's price. Additionally, you may evaluate how the addition of InspireMD to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

InspireMD Historical Income Statement

About InspireMD Income Statement Analysis

InspireMD Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Total Revenue

InspireMD income statement Correlations

InspireMD Account Relationship Matchups

High Positive Relationship

High Negative Relationship

InspireMD income statement Accounts

Pair Trading with InspireMD

Moving together with InspireMD Stock

Moving against InspireMD Stock

Additional Tools for InspireMD Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Total Operating Expenses	+ 0.99	Other Operating Expenses
Income Before Tax	+ 0.88	Operating Income

Total Operating Expenses	- 0.95	Ebitda
Total Operating Expenses	- 0.95	Ebit
Total Operating Expenses	- 0.95	Operating Income
Total Other Income Expense Net	- 0.95	Interest Expense
Ebitda	- 0.93	Other Operating Expenses
Ebit	- 0.93	Other Operating Expenses